Swedbank AB Has $60.10 Million Position in Medtronic PLC $MDT

Swedbank AB grew its position in shares of Medtronic PLC (NYSE:MDT) by 2.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 625,686 shares of the medical technology company’s stock after purchasing an additional 15,714 shares during the quarter. Swedbank AB’s holdings in Medtronic were worth $60,103,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Artisan Partners Limited Partnership boosted its holdings in Medtronic by 2.6% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after acquiring an additional 31,314 shares during the last quarter. SageView Advisory Group LLC boosted its holdings in shares of Medtronic by 164.8% in the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 15,062 shares during the last quarter. CSM Advisors LLC boosted its holdings in shares of Medtronic by 13.2% in the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after buying an additional 33,167 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Medtronic by 65.8% in the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after buying an additional 54,898 shares during the last quarter. Finally, Applied Finance Capital Management LLC purchased a new position in shares of Medtronic in the 3rd quarter worth about $1,308,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory and clinical progress for electrophysiology assets: Medtronic highlighted momentum for the Affera electrophysiology platform and noted an FDA Breakthrough Device designation, a potential catalyst for commercial adoption in arrhythmia treatment. Medtronic highlights Affera momentum and FDA Breakthrough Device designation
• Positive Sentiment: CE mark granted for VitalFlow ECMO transport technology, validating a commercial pathway in critical?care transport and supporting incremental device revenue opportunities. Medtronic wins CE mark for VitalFlow ECMO transport tech
• Positive Sentiment: Strategic investment signaling continued partnership activity: Medtronic fulfilled a $20M financing commitment to Orchestra BioMed under an existing collaboration to support the BACKBEAT pivotal trial for AVIM therapy, showing Medtronic’s continued investment in outside innovation and potential future pipeline upside (amount is modest relative to MDT’s scale). Orchestra BioMed receives $20M payment from Medtronic
• Neutral Sentiment: Related financing news for Orchestra: Ligand made a $15M tranche to Orchestra under a royalty?based financing agreement; combined with Medtronic funding this brings additional capital to Orchestra but has limited direct impact on Medtronic’s near?term fundamentals. Orchestra BioMed receives $15M from Ligand
• Neutral Sentiment: Market research & sentiment pieces are parsing whether Wall Street is bullish or bearish on MDT, reflecting divergent analyst takes rather than a single consensus driver. That debate is keeping trading choppy. Medtronic stock outlook: Is Wall Street bullish or bearish?
• Negative Sentiment: Near?term selling pressure and price weakness: Market reports note MDT shares have pulled back amid profit?taking and skepticism from some analysts about growth versus the guidance range; that has pressured the stock despite earnings that modestly beat estimates. Medtronic (MDT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Mixed analyst reactions and a small trim to fair?value estimates: Some research shops have slightly lowered targets or expressed caution on guidance execution and the timing of new product rollouts, creating downward pressure on the stock. How The Medtronic (MDT) Story Is Shifting As Guidance Meets Mixed Wall Street Views

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on MDT shares. Truist Financial cut their price target on shares of Medtronic from $103.00 to $95.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Piper Sandler cut their price target on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a report on Wednesday, April 1st. JPMorgan Chase & Co. cut their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Weiss Ratings downgraded shares of Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, April 21st. Finally, Argus cut their price target on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and an average target price of $107.80.

Medtronic Trading Down 0.2%

Shares of Medtronic stock opened at $77.64 on Thursday. Medtronic PLC has a 52-week low of $77.16 and a 52-week high of $106.33. The stock’s 50-day simple moving average is $87.64 and its 200 day simple moving average is $94.55. The stock has a market capitalization of $99.68 billion, a P/E ratio of 21.63, a P/E/G ratio of 1.85 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the previous year, the business posted $1.38 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts anticipate that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date was Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).